Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 23, 2020 08:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53

PC14586 targets p53 Y220C mutants to selectively reactivate p53, restoring the protein’s tumor-suppressing functionPhase 1/2 study is enrolling patients with advanced solid tumors that have a p53...
November 13, 2020 08:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights

U.S. Food and Drug Administration (FDA) clearance of PMV Pharmaceutical’s investigational new drug application for its lead product candidate PC14586PMV Pharma lead product candidate PC14586 granted...
October 13, 2020 08:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation

CRANBURY, N.J., Oct. 13, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., (Nasdaq: PMVP) a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic...
September 29, 2020 16:05 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharma Announces Closing of $243.5 Million Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

CRANBURY, N.J., Sept. 29, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies...
September 24, 2020 20:06 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharma Announces Pricing of Initial Public Offering

CRANBURY, N.J., Sept. 24, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies...
September 08, 2020 08:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharma Appoints Laurie Stelzer to the Board of Directors and Robert Ticktin as General Counsel

CRANBURY, N. J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies...
August 03, 2020 08:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharma Closes $70 Million in Series D Financing

CRANBURY, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies...
December 11, 2019 08:00 ET | Source: PMV Pharmaceuticals, Inc.

PMV Pharma Appoints Leila Alland, M.D., as Chief Medical Officer

CRANBURY, N.J., Dec. 11, 2019 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc., a leader in the discovery and development of p53-targeted small molecule drugs for the treatment of cancer, today...